1. Reineke U, Ebmeyer J, Schütte F, Upile T, Sudhoff HH. Tophaceous gout of the middle ear. Otol Neurotol. 2009; 30:127–8.
Article
2. Saliba I, Bouthiller A, Desrochers P, Berthlet F, Dufour JJ. Tophaceous gout and pseudogout of the middle ear and the infratemporal fossa: case report and review of the literature. J Otolaryngol. 2003; 32:269–72.
Article
3. Stark TW, Hirokawa RH. Gout and its manifestations in the head and neck. Otolaryngol Clin North Am. 1982; 15:659–64.
Article
4. Forbess LJ, Fields TR. The broad spectrum of urate crystal deposition: unusual presentations of gouty tophi. Semin Arthritis Rheum. 2012; 42:146–54.
Article
5. Antón FM, García Puig J, Ramos T, González P, Ordás J. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. Metabolism. 1986; 35:343–8.
6. Puig JG, Michán AD, Jiménez ML, Pérez de Ayala C, Mateos FA, Capitán CF, et al. Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med. 1991; 151:726–32.
Article
7. Logan JA, Morrison E, McGill PE. Serum uric acid in acute gout. Ann Rheum Dis. 1997; 56:696–7.
Article
8. Park YB, Park YS, Lee SC, Yoon SJ, Lee SK. Clinical analysis of gouty patients with normouricaemia at diagnosis. Ann Rheum Dis. 2003; 62:90–2.
Article
9. Schlesinger N, Norquist JM, Watson DJ. Serum urate during acute gout. J Rheumatol. 2009; 36:1287–9.
Article
10. Firestein GS BR, Gabriel SE, McInnes IB, O'Dell JR. Kelley' s textbook of rheumatology. 9th ed.p. 1556. Philadelphia: Elsevier Saunders;2013.
11. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002; 47:356–60.
Article